Strata Partners advises Capita plc on the divestment of its 75% shareholding in Fera Science Ltd based on an EV for the joint venture of £80m

Strata Partners is delighted to announce our latest TIC sector transaction, advising Capita plc (“Capita”) on the sale of its 75% shareholding in Fera Science Limited (“Fera”) to Bridgepoint Group plc (“Bridgepoint”) for an enterprise value of £60 million on a cash-free, debt-free basis. The deal values the total joint venture at £80 million.

Read More Download Press Release

Strata Partners advises Normec on the acquisition of i2 Analytical

Strata Partners is delighted to announce that it arranged and acted as exclusive corporate finance adviser to Normec, the European TICC sector consolidator and a portfolio company of private equity firm, Astorg, in relation to the acquisition of i2 Analytical, the UK-market leading provider of environmental, construction materials and food testing services i2 Analytical.

Read More Download Press Release

Strata Partners advises Forensic Access on the acquisition of Analytical Services International Limited

Strata Partners is delighted to announce that it arranged, and acted as exclusive corporate finance adviser to Forensic Access (a portfolio company of Limerston Capital) in relation to, the acquisition of leading bioanalysis and toxicology laboratory services provider Analytical Services International
Limited (“ASI”).

Read More Download Press Release

Strata Partners advises Limerston Capital on the acquisition of Wickham Micro

Strata Partners is delighted to announce that it arranged and acted as exclusive corporate finance adviser to Limerston Capital in relation to their recent acquisition of the microbiology and in-vitro toxicology testing activities of Gosport, UK-based Wickham Laboratories to form a new, standalone business, Wickham Micro.

Read More Download Press Release

Strata Partners advises Pharmaron on the acquisition of Absorption Systems

Strata Partners is delighted to announce that it acted as exclusive corporate finance adviser to Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”), a fully integrated contract research and manufacturing organization offering laboratory, CMC and clinical development services for the life science industry, on its acquisition of 100% of the equity of Absorption Systems for up to US$137.5 million in cash.

Read More Download Press Release